title: Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.
abstract: Patients with type 2 diabetes mellitus have an increased risk of chronic liver disease (CLD) such as non-alcoholic fatty liver disease and steatohepatitis, and about one-third of cirrhotic patients have diabetes. However, the use of several antidiabetic agents, such as metformin and sulphonylureas, may be a concern in case of hepatic impairment (HI). New glucose-lowering agents targeting the incretin system are increasingly used for the management of type 2 diabetes. Incretin-based therapies comprise oral inhibitors of dipeptidyl peptidase-4 (DPP-4) (gliptins) or injectable glucagon-like peptide-1 (GLP-1) receptor agonists. This narrative review summarises the available data regarding the use of both incretin-based therapies in patients with HI. In contrast to old glucose-lowering agents, they were evaluated in specifically designed acute pharmacokinetic studies in patients with various degrees of HI and their hepatic safety was carefully analysed in large clinical trials. Only mild changes in pharmacokinetic characteristics of DPP-4 inhibitors were observed in patients with different degrees of HI, presumably without major clinical relevance. GLP-1 receptor agonists have a renal excretion rather than liver metabolism. Specific pharmacokinetic data in patients with HI are only available for liraglutide. No significant changes in liver enzymes were reported with DPP-4 inhibitors or GLP-1 receptor agonists, alone or in combination with various other glucose-lowering agents, in clinical trials up to 2 years in length. On the contrary, preliminary data suggested that incretin-based therapies may be beneficial in patients with CLD, more particularly in the presence of non-alcoholic fatty liver disease. Nevertheless, caution should be recommended, especially in patients with advanced cirrhosis, because of a lack of clinical experience with incretin-based therapies in these vulnerable patients.
authors.affiliation: Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, University of Liège, Liège, Belgium, andre.scheen@chu.ulg.ac.be.
authors.forename: André J
authors.initials: AJ
authors.lastname: Scheen
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D054795:Incretins / Q000493:pharmacokinetics / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008107:Liver Diseases / Q000188:drug therapy / Q000378:metabolism*; D018027:Receptors, Glucagon / Q000819:agonists*
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D054795:Incretins; D018027:Receptors, Glucagon
references.citation: Expert Opin Drug Metab Toxicol. 2013 May;9(5):529-50
references.pmid: 23461781
references.citation: Acta Biomed. 2011 Aug;82(2):160-1
references.pmid: 22480072
references.citation: Hepatogastroenterology. 2012 Jul-Aug;59(117):1522-5
references.pmid: 22155853
references.citation: Eur J Clin Pharmacol. 2007 Jul;63(7):677-86
references.pmid: 17486328
references.citation: Drug Metab Dispos. 2010 Nov;38(11):1944-53
references.pmid: 20709939
references.citation: Acta Gastroenterol Belg. 2012 Jun;75(2):240-4
references.pmid: 22870790
references.citation: Diabetes Obes Metab. 2010 Aug;12(8):648-58
references.pmid: 20590741
references.citation: Hepatol Res. 2015 Mar;45(3):269-78
references.pmid: 24796231
references.citation: Hepatobiliary Pancreat Dis Int. 2013 Dec;12(6):584-8
references.pmid: 24322742
references.citation: JAMA Intern Med. 2014 Jun;174(6):984-7
references.pmid: 24733687
references.citation: BMJ Open. 2013 Nov 04;3(11):e003995
references.pmid: 24189085
references.citation: Diabetologia. 2012 Jun;55(6):1577-96
references.pmid: 22526604
references.citation: Case Rep Gastroenterol. 2012 May;6(2):538-44
references.pmid: 22949894
references.citation: N Engl J Med. 2013 Oct 3;369(14):1327-35
references.pmid: 23992602
references.citation: Clin Endocrinol (Oxf). 2014 Oct;81(4):523-8
references.pmid: 24256515
references.citation: Ann Hepatol. 2009 Jan-Mar;8(1):13-20
references.pmid: 19221528
references.citation: Arq Bras Endocrinol Metabol. 2013 Dec;57(9):702-8
references.pmid: 24402015
references.citation: Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):839-57
references.pmid: 24669954
references.citation: Endocrine. 2014 Aug;46(3):406-19
references.pmid: 24510630
references.citation: Br J Hosp Med (Lond). 2011 Sep;72(9):497-503
references.pmid: 22041830
references.citation: Intern Med. 2011;50(9):1015-20
references.pmid: 21532224
references.citation: Diabetes Obes Metab. 2010 Jun;12(6):495-509
references.pmid: 20518805
references.citation: Diabetes Obes Metab. 2012 May;14(5):470-8
references.pmid: 22268497
references.citation: Diabetes. 2014 Nov;63(11):3637-46
references.pmid: 24947350
references.citation: Br J Clin Pharmacol. 2010 Dec;70(6):807-14
references.pmid: 21175436
references.citation: Hepatol Res. 2013 Nov;43(11):1163-8
references.pmid: 23489256
references.citation: ScientificWorldJournal. 2012;2012:496453
references.pmid: 22927782
references.citation: Hepatology. 1994 Mar;19(3):616-27
references.pmid: 8119686
references.citation: Diabetes Care. 2007 Mar;30(3):734-43
references.pmid: 17327353
references.citation: N Engl J Med. 2013 Oct 3;369(14):1317-26
references.pmid: 23992601
references.citation: Br J Clin Pharmacol. 2012 Jul;74(1):75-85
references.pmid: 22242621
references.citation: Clin Pharmacokinet. 2012 Aug 1;51(8):501-14
references.pmid: 22686547
references.citation: Ann Pharmacother. 2010 Feb;44(2):394-5
references.pmid: 20103614
references.citation: Expert Opin Drug Metab Toxicol. 2011 Dec;7(12):1561-76
references.pmid: 22022857
references.citation: J Hepatol. 1989 Jan;8(1):107-14
references.pmid: 2646365
references.citation: Postgrad Med. 2012 Jul;124(4):130-7
references.pmid: 22913901
references.citation: Expert Opin Drug Saf. 2013 Jan;12(1):103-9
references.pmid: 23137182
references.citation: PLoS One. 2012;7(12):e50117
references.pmid: 23236362
references.citation: Diabetes Obes Metab. 2012 Dec;14(12):1061-72
references.pmid: 22519906
references.citation: Aliment Pharmacol Ther. 2013 Jan;37(2):234-42
references.pmid: 23163663
references.citation: Expert Opin Pharmacother. 2013 Nov;14(16):2281-96
references.pmid: 24087882
references.citation: World J Gastroenterol. 2011 Dec 28;17(48):5240-5
references.pmid: 22219592
references.citation: Hepatogastroenterology. 2014 Mar-Apr;61(130):323-8
references.pmid: 24901133
references.citation: World J Gastroenterol. 2013 Apr 21;19(15):2298-306
references.pmid: 23613622
references.citation: Exp Diabetes Res. 2012;2012:716404
references.pmid: 22194737
references.citation: Vasc Health Risk Manag. 2011;7:49-57
references.pmid: 21415917
references.citation: Eur J Clin Pharmacol. 2008 Dec;64(12):1147-61
references.pmid: 18762933
references.citation: Lancet. 2006 Nov 11;368(9548):1696-705
references.pmid: 17098089
references.citation: Diabet Med. 2012 Sep;29(9):1098-107
references.pmid: 22672330
references.citation: Diabetes Metab. 2014 Feb;40(1):82-84
references.pmid: 24378344
references.citation: Hepatol Res. 2011 Jun;41(6):524-9
references.pmid: 21435130
references.citation: Nat Rev Endocrinol. 2012 Dec;8(12):728-42
references.pmid: 22945360
references.citation: Curr Drug Metab. 2006 May;7(4):367-74
references.pmid: 16724926
references.citation: Hepatol Res. 2013 Jan;43(1):51-64
references.pmid: 23332087
references.citation: Diabetes. 2008 May;57(5):1340-8
references.pmid: 18162504
references.citation: Diabetes Metab Res Rev. 2006 Jul-Aug;22(4):274-83
references.pmid: 16506276
references.citation: Drug Saf. 2013 Oct;36(10):981-7
references.pmid: 23743694
references.citation: World J Gastroenterol. 2014 Jun 21;20(23):7356-65
references.pmid: 24966606
references.citation: PLoS One. 2014 Jan 29;9(1):e87488
references.pmid: 24489924
references.citation: Can J Clin Pharmacol. 2009 Winter;16(1):e165-70
references.pmid: 19221403
references.citation: Clin Ther. 2007 Jan;29(1):139-53
references.pmid: 17379054
references.citation: Diabetes Metab. 2013 Dec;39(6):485-96
references.pmid: 24156868
references.citation: Int J Mol Sci. 2013 Nov 20;14(11):22933-66
references.pmid: 24264040
references.citation: Clin Pharmacokinet. 2012 Mar 1;51(3):147-62
references.pmid: 22339447
references.citation: N Engl J Med. 2006 Feb 16;354(7):731-9
references.pmid: 16481640
references.citation: Drug Metab Dispos. 2007 Apr;35(4):533-8
references.pmid: 17220239
references.citation: Diabetes Metab Res Rev. 2014 Sep;30(6):521-9
references.pmid: 24823873
references.citation: Expert Opin Pharmacother. 2012 Jan;13(1):81-99
references.pmid: 22149369
references.citation: Ann Hepatol. 2007 Oct-Dec;6(4):242-50
references.pmid: 18007554
references.citation: Clin Pharmacokinet. 2011 Apr;50(4):253-65
references.pmid: 21348538
references.citation: Am J Gastroenterol. 2010 Dec;105(12):2707-9
references.pmid: 21131943
references.citation: Drugs. 2010 Oct 22;70(15):2051-72
references.pmid: 20883057
references.citation: Hepatogastroenterology. 2011 Nov-Dec;58(112):2103-5
references.pmid: 22024083
references.citation: Expert Opin Drug Metab Toxicol. 2013 Jan;9(1):17-29
references.pmid: 23094590